Compare Biocon Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GLENMARK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GLENMARK PHARMA BIOCON /
GLENMARK PHARMA
 
P/E (TTM) x 27.4 13.7 199.9% View Chart
P/BV x 3.5 1.8 201.4% View Chart
Dividend Yield % 0.3 0.6 48.5%  

Financials

 BIOCON    GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
GLENMARK PHARMA
Mar-19
BIOCON /
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs707712 99.4%   
Low Rs554484 114.5%   
Sales per share (Unadj.) Rs91.9349.6 26.3%  
Earnings per share (Unadj.) Rs16.732.8 51.0%  
Cash flow per share (Unadj.) Rs24.244.3 54.5%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.3 47.4%  
Book value per share (Unadj.) Rs101.6198.6 51.2%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.7 401.4%   
Avg P/E ratio x37.718.2 207.0%  
P/CF ratio (eoy) x26.113.5 193.5%  
Price / Book Value ratio x6.23.0 206.2%  
Dividend payout %6.06.1 98.1%   
Avg Mkt Cap Rs m378,330168,625 224.4%   
No. of employees `0006.112.0 50.9%   
Total wages/salary Rs m11,65320,561 56.7%   
Avg. sales/employee Rs Th8,994.38,196.0 109.7%   
Avg. wages/employee Rs Th1,900.71,708.1 111.3%   
Avg. net profit/employee Rs Th1,635.3768.5 212.8%   
INCOME DATA
Net Sales Rs m55,14498,655 55.9%  
Other income Rs m1,4442,081 69.4%   
Total revenues Rs m56,588100,736 56.2%   
Gross profit Rs m15,88315,858 100.2%  
Depreciation Rs m4,4783,259 137.4%   
Interest Rs m7093,346 21.2%   
Profit before tax Rs m12,14011,335 107.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,1233,756 56.5%   
Profit after tax Rs m10,0269,250 108.4%  
Gross profit margin %28.816.1 179.2%  
Effective tax rate %17.533.1 52.8%   
Net profit margin %18.29.4 193.9%  
BALANCE SHEET DATA
Current assets Rs m48,22866,968 72.0%   
Current liabilities Rs m30,37640,211 75.5%   
Net working cap to sales %32.427.1 119.4%  
Current ratio x1.61.7 95.3%  
Inventory Days Days6883 82.0%  
Debtors Days Days8681 105.3%  
Net fixed assets Rs m64,13033,322 192.5%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m57,98055,770 104.0%   
Net worth Rs m60,98056,052 108.8%   
Long term debt Rs m15,76635,738 44.1%   
Total assets Rs m121,924132,888 91.7%  
Interest coverage x18.14.4 413.0%   
Debt to equity ratio x0.30.6 40.6%  
Sales to assets ratio x0.50.7 60.9%   
Return on assets %8.89.5 92.9%  
Return on equity %16.416.5 99.6%  
Return on capital %16.817.8 94.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50662,998 24.6%   
Fx outflow Rs m10,39922,859 45.5%   
Net fx Rs m5,10740,140 12.7%   
CASH FLOW
From Operations Rs m11,54613,242 87.2%  
From Investments Rs m-7,138-6,990 102.1%  
From Financial Activity Rs m-2,417-7,387 32.7%  
Net Cashflow Rs m2,103-2,971 -70.8%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Crude Oil Sees Buying, FPI Equity Inflows Rise, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended marginally lower yesterday as benchmark indices gave up early gains and slipped into the red during the last hour of trading.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 26, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS